Skip to main content

Table 2 Baseline characteristics of VARA participants at the start of each biologic treatment episode

From: Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis

Characteristics Biologics only (N= 197) Biologics or DMARDs* (N= 305)
Patient demographics   
   Age, years 60.9 ± 10.3 62.3 ± 10.4
   Males 185 (94%) 287 (94%)
   Race/ethnicity   
   Caucasian, non-Hispanic 159 (81%) 248 (81%)
   Non-Caucasian, Hispanic 7 (4%) 8 (3%)
   Black, non-Hispanic 27 (14%) 45 (15%)
   American Indian or Pacific Islander 4 (2%) 4 (1%)
RA drug initiated   
   Abatacept 9 (5%) 9 (3%)
   Adalimumab 74 (38%) 74 (24%)
   Etanercept 60 (31%) 60 (20%)
   Infliximab 34 (17%) 34 (11%)
   Rituximab 20 (10%) 20 (7%)
   Hydroxychloroquine n/a 63 (21%)
   Leflunomide n/a 20 (7%)
   Sulfasalazine n/a 25 (8%)
RA-related characteristics   
   DAS28 5.0 ± 1.5 4.9 ± 1.6
   CDAI (0-76) 30.2 ± 16.3 27.5 ± 15.2
   Physician global (0 to 100) 51.0 ± 22.1 50.3 ± 22.6
   Patient global (0 to 100) 57.4 ± 25.2 54.8 ± 24.2
   Tender joint count (0 to 28) 9.6 ± 8.6 8.5 ± 7.9
   Swollen joint count (0 to 28) 7.9 ± 7.2 7.8 ± 6.6
   MDHAQ (0 to 3) 1.2 ± 0.6 1.2 ± 0.6
   ESR, mm/hour 27.9 ± 23.3 29.9 ± 24.6
   CRP, mg/dL 1.9 ± 2.4 2.1 ± 2.5
  1. Data are n (%) or means ± SD. DMARD: disease-modifying agent; RA: rheumatoid arthritis; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; MDHAQ: Multi-Dimensional Health Assessment Questionnaire; ESR: sedimentation rate; n/a: not applicable; SD: standard deviation. *Includes hydroxychloroquine, leflunomide and sulfasalazine.